Eris Lifesciences · NSE: ERIS · BSE: 540596
Q3 FY19 results · Oct–Dec 2018
Eris Lifesciences reported revenue from operations of ₹252.40 crore and net profit of ₹80.20 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 252.40 | — | — | 264.18 | −4.5% |
| Other income | 10.29 | — | — | 6.15 | +67.2% |
| Total income | 262.68 | — | — | 270.34 | −2.8% |
| Profit before tax | 89.11 | — | — | 92.31 | −3.5% |
| Net profit for the period | 80.20 | — | — | 85.51 | −6.2% |
| Attributable to shareholders of the company | 80.14 | — | — | 85.32 | −6.1% |
| EPS, basic (₹) | 5.83 | — | — | 6.20 | −6.0% |
| Net margin (%) | 31.8 | — | 32.4 |
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 230.80 | — | — | 240.81 | −4.2% |
| Other income | 10.15 | — | — | 6.24 | +62.8% |
| Total income | 240.96 | — | — | 247.05 | −2.5% |
| Profit before tax | 87.27 | — | — | 89.99 | −3.0% |
| Net profit for the period | 78.88 | — | — | 83.98 | −6.1% |
| EPS, basic (₹) | 5.74 | — | — | 6.10 | −5.9% |
| Net margin (%) | 34.2 | — | 34.9 |
Consolidated
- Filed with BSE
- 30 Jan 2019, 12:30 IST
- Board meeting
- 29 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2019, 12:30 IST
- Board meeting
- 29 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE